With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments
Fierce Biotech
-
- tags:
- Obesity
- ARCH Venture Partners
- biotech venture capital
- The Medicines Company
- Eli Lilly
- Novo Nordisk
- Leqvio
- Novartis
- F-Prime Capital
- Metabolic disorders
- GLP-1
- Newpath Partners
- Emerging Biopharma
- Biotech
- Fierce Biotech Homepage
- Venture Capital
- GLP-1 receptor agonist
- Anti-obesity medication
- Eli Lilly and Company
- Biotechnology
- Medicines Company (The)
- Startup company
- Metabolic disorder